Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study

AIMS: Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD‐PAH) after defect correction have a poor prognosis compared with other CHD‐PAH patients. Therefore, it is important that these patients are treated as early and effectively as possible. Evidence support...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur J Heart Fail
Main Authors: Beghetti, Maurice, Channick, Richard N., Chin, Kelly M., Di Scala, Lilla, Gaine, Sean, Ghofrani, Hossein‐Ardeschir, Hoeper, Marius M., Lang, Irene M., McLaughlin, Vallerie V., Preiss, Ralph, Rubin, Lewis J., Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F., Galiè, Nazzareno
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Ltd 2019
Assuntos:
Clinical Trials
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6607487/
https://ncbi.nlm.nih.gov/pubmed/30632656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.1375
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares